NADAC acquisition cost data for LUPRON DEPOT 11.25 MG 3MO KIT. This is a brand-name medication — generic alternatives may be available at lower prices.
| Generic Name | leuprolide acetate |
| Brand Name | Lupron Depot-PED |
| Manufacturer | AbbVie Inc. |
| Dosage Form | KIT |
| Product Type | HUMAN PRESCRIPTION DRUG |
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00074366303 | $4,546.75 | 2022-01-14 | Rx |
| 00074366303 | $4,546.75 | 2022-01-14 | Rx |
| 00074366303 | $4,546.75 | 2022-01-14 | Rx |
| 00074366303 | $4,546.75 | 2022-01-14 | Rx |
| 00074366303 | $4,546.75 | 2022-01-14 | Rx |
| 00074366303 | $4,546.75 | 2022-01-14 | Rx |
| 00074366303 | $4,546.75 | 2022-01-14 | Rx |
| 00074366303 | $4,546.75 | 2022-01-14 | Rx |
| 00074366303 | $4,546.75 | 2022-01-14 | Rx |
| 00074366303 | $4,546.75 | 2022-01-14 | Rx |
Generic: Leuprolide Acetate | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $2.5M | 1,554 | 760 | $1,580.19 |
| 2020 | $5.7M | 3,730 | 2,292 | $1,499.67 |
| 2021 | $7.4M | 4,966 | 2,259 | $1,484.77 |
| 2022 | $8.1M | 5,688 | 2,377 | $1,413.35 |
| 2023 | $9.9M | 7,036 | 2,942 | $1,401.71 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| Florida | $2.4M | 1,911 | 748 |
| New York | $1.6M | 1,123 | 483 |
| California | $1.6M | 1,196 | 464 |
| Pennsylvania | $557.6K | 323 | 153 |
| New Jersey | $434.4K | 309 | 125 |
| Texas | $377.6K | 257 | 115 |
| Hawaii | $292.3K | 248 | 89 |
| Ohio | $232.0K | 120 | 66 |
| Puerto Rico | $213.5K | 215 | 65 |
| South Carolina | $206.5K | 124 | 56 |
| Tennessee | $164.0K | 79 | 49 |
| Maryland | $142.8K | 108 | 44 |
| Illinois | $135.1K | 88 | 43 |
| Michigan | $130.0K | 64 | 35 |
| Rhode Island | $113.6K | 43 | 27 |
| Maine | $105.8K | 76 | 44 |
| Arkansas | $104.8K | 81 | 39 |
| Georgia | $104.4K | 63 | 33 |
| Massachusetts | $102.3K | 67 | 31 |
| Kentucky | $90.4K | 46 | 22 |
| Louisiana | $79.5K | 64 | 18 |
| Oklahoma | $75.8K | 39 | 23 |
| West Virginia | $51.4K | 21 | 15 |
| North Carolina | $41.1K | 37 | 18 |
| Nevada | $39.5K | 22 | 16 |
| Indiana | $37.7K | 23 | 12 |
| Washington | $32.6K | 23 | 12 |
| Mississippi | $32.1K | 24 | N/A |
| Iowa | $31.1K | 39 | N/A |
| Kansas | $30.7K | 21 | N/A |
| Virginia | $28.6K | 16 | N/A |
| Wisconsin | $26.1K | 24 | N/A |
| Minnesota | $23.4K | 14 | N/A |
| Missouri | $22.9K | 13 | N/A |
| Oregon | $19.8K | 11 | N/A |
| Arizona | $19.4K | 11 | N/A |
| Alaska | $18.4K | 16 | N/A |
| Utah | $8.8K | 12 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.